论文部分内容阅读
慢性阻塞性肺疾病(COPD)常合并慢性心力衰竭,虽然肾上腺素β受体(β受体)阻滞药作为治疗慢性心力衰竭的基础药物,但长期被认为是治疗COPD的禁忌证。近来有研究报道,长期使用心脏选择性β受体阻滞药可降低COPD患者的死亡率并提高生活质量。本文就COPD患者中应用β受体阻滞药的研究进展进行综述。
Chronic Obstructive Pulmonary Disease (COPD) is often associated with chronic heart failure. Although adrenergic beta-adrenergic receptor blockers are the primary drug for the treatment of chronic heart failure, they have long been considered contraindications to COPD. Recent studies have reported that long-term use of cardiac selective β-blockers can reduce mortality and improve quality of life in COPD patients. This article reviews the research progress of β-blockers in COPD patients.